Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 315 for lung cancer

Edit search filters
  1. Study of BLU-667 in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination with Crizotinib

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

    Rochester, MN

  4. BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Erlotinib with or without Bevacizumab in Treating Patients with Stage IV Non-Small Cell Lung Cancer with EGFR Mutations

    Rochester, MN

  6. Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

    Rochester, MN, Scottsdale/Phoenix, AZ

  7. Combination Vaccine Immunotherapy (DRibbles) for Patients with Definitively-treated Stage III Non-small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  8. Study of Pembrolizumab With Ipilimumab or Placebo in Participants with Untreated Metastatic Non-small Cell Lung Cancer

  9. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).

    Scottsdale/Phoenix, AZ

  10. Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer

    Rochester, MN

.

Mayo Clinic Footer